Graft-versus-host disease (GVHD) is a common and severe complication that occurs after stem cell transplantation, where the ...

Experts from five states have sounded the alarm about blockbuster weight loss drugs like Ozempic leaving users blind, ...

Loss to follow-up higher among men who are Black or Hispanic, or those who must travel farther to care facilities.

A new review reports that nine people taking semaglutide and tirzepatide — the active ingredient in GLP-1 medications — experienced vision issues, including three potentially blinding eye conditions.

The following is a summary of “Evaluating lipid-lowering drug targets for full-course diabetic retinopathy,” published in the ...

The U.S. Food and Drug Administration has approved Genentech's Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular ...

The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.

Researchers have conducted one of the largest eye studies in the world to reveal new insights into retinal thickness, highlighting its potential in the early detection of diseases like type 2 diabetes ...

Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled every six months with an already ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...

The ranibizumab injection delivered through an implant device could be administered in a convenient schedule twice per year ...

Seven months after the FDA signed off on a reintroduction of Roche’s eye implant Susvimo, the U.S. regulator has broadened ...